AGENUS INC. (NASDAQ:AGEN) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On March 9, 2017, Agenus Inc. announced its financial results for
the quarter and year ended December 31, 2016. The full text of
the press release issued in connection with the announcement is
being furnished as Exhibit 99.1 to this current report on Form
8-K.
The information set forth under Item 2.02 and in Exhibit99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as expressly set
forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated March 9, 2017
About AGENUS INC. (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. AGENUS INC. (NASDAQ:AGEN) Recent Trading Information
AGENUS INC. (NASDAQ:AGEN) closed its last trading session up +0.16 at 4.13 with 763,381 shares trading hands.
